MINNEAPOLIS, Oct. 29, 2025 — VentureMed Group, Inc., a leading medical device company specializing in vessel preparation and access management technologies for the treatment of peripheral arterial disease (PAD) and arteriovenous fistulas and grafts (AVF, AVG), today announced the closing of a $28 million Series C financing round led by S3 Ventures, and joined by existing investors including Endeavour Vision.

“As we enter our next phase, we are grateful for the continued support of our existing investors and excited to welcome new partners to the syndicate,” said Denis Harrington, President and CEO of VentureMed. “This significant financing underscores investor confidence in the FLEX Vessel Prep™ System and our mission to strengthen VentureMed’s position in global vascular care.”

In addition to expanded commercial infrastructure, the funding will also advance VentureMed’s clinical program and support new product development, including new applications in adjacent vascular settings.

“VentureMed is addressing one of the most persistent challenges in vascular access with a technology that is both elegant and transformative,” said Brian R. Smith, Managing Director at S3 Ventures. “Our partnership reflects a shared mission to bring breakthrough treatments to those who need them most.”

Vascular diseases are a growing burden globally, driven by the rise in obesity, diabetes and hypertension. PAD affects more than 20 million people in the U.S. and over 200 million worldwide¹, while stenosis and vessel dysfunction remain major causes of access failure in dialysis patients. FLEX was developed to improve vessel compliance, minimize trauma, and support better long-term outcomes. “Lesion prep is rapidly becoming one of the most important procedures for improving patient outcomes. The FLEX VP system is leading the way in addressing AV Access interventions,” said Dr. Ari Kramer, General Surgeon, Spartanburg Medical Center. “This fundraising is an important milestone as the company advances additional clinical evidence and expanded indications.”

Already FDA 510(k)-cleared, CE Mark-approved, and supported in the U.S. by a dedicated CMS HCPCS code (C1600) with transitional pass-through payment, FLEX is positioned to redefine vessel preparation and potentially expand treatment options worldwide.

“The cycle of re-narrowing and repeat procedures in vascular disease places a significant burden on patients and health systems,” said Alexander Schmitz, Partner at Endeavour Vision. “A technology that reduces the need for reinterventions not only improves outcomes but also aligns with the shift to value-based care. We’re excited to continue supporting VentureMed as it expands access to this important therapy.”

About VentureMed Group & FLEX Vessel Prep™ System
VentureMed Group, Inc. is a pioneering privately held medical device company based in Minnesota dedicated to advancing endovascular solutions for arteriovenous (AV) access and peripheral arterial disease (PAD) interventions. The company’s flagship technology, the FLEX Vessel Prep™ System, is an FDA 510(k)-cleared and CE Mark-approved device, that is designed to optimize vessel preparation using its proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology. Unlike traditional balloon-based approaches that apply static pressure, KEMIC leverages controlled motion and dynamic vessel apposition to create long, precise micro-incisions. This unique mechanism facilitates luminal gain, may enhance drug uptake when used in combination therapy, and may reduce vessel trauma – ultimately lowering the risk of restenosis. For more information, visit www.VentureMedgroup.com.

References: 1. Allison M.A. et al.Circulation. 2023;148:286–296.

Media contact: Tom Michals
[email protected]
+1(763) 951-0280

Logo – https://mma.prnewswire.com/media/658751/VentureMed_Group_Logo.jpg

As wage pressures, regulation, and caregiver shortages strain post-acute providers, Arya is using AI to automate non-clinical administration, freeing resources to focus on care

NEW YORK, Oct. 29, 2025 — Arya Health (Arya), an AI company helping home health and post-acute care providers automate scheduling, compliance, and other administrative operations, announced today its $18.2 million Series A funding. The round was led by ACME Capital, with participation from Ridge Ventures, Twelve Below, executives from OpenAI, and leading post-acute care providers, bringing Arya’s total funding to $25 million.

Post-acute care providers, including home healthcare agencies, hospice providers, and long-term care facilities, are facing unprecedented strain. Rapid regulatory changes, caregiver shortages, and escalating wage pressures are pushing an already margin-constrained industry to the brink. Meanwhile, heavy private equity investment and consolidation call for a renewed focus on operational excellence and thinking beyond the traditional “people-heavy” approach to post-acute care administration.

Arya is building a new AI-native “system of action” that sits alongside the Electronic Medical Record (EMR) to automate the heavy administrative load that burdens front office teams, slows growth, and diverts resources from patient care and caregiver support.

“Post-acute care organizations spend roughly 25 cents of every dollar on non-clinical tasks,” said Kunal Sarda, CEO and co-founder of Arya Health. “That’s time and money that should be going toward caregivers and patients, not process. Arya is flipping that equation by using AI to take on the operational burden so providers can focus on delivering care, not moving patients, caregivers, and data around in their EMR. Our mandate is to make post-acute care administration more scalable, human, and cost-effective at the same time.”

Arya’s AI-powered digital agents automate key post-acute care workflows, including caregiver scheduling, compliance tracking, and hiring pipeline management. Embedded in daily operations, these agents continuously learn and adapt to increase workforce efficiency. Recent innovations include the Onboarding Agent, which reduces time-to-first-staffing by 50% with 70% less administrative effort; the Talent Acquisition Agent, which autonomously recruits and schedules caregivers with 60% less human effort; and the Compliance Agent, which eliminates manual license tracking and deploys in just one week. The company is also preparing to launch an Intake Agent in Q4, designed to accelerate patient start of care and reduce critical back-office bottlenecks.

The new funding will enable Arya to expand its product suite across additional administrative functions and scale hiring to keep pace with market demand. Arya has grown revenue more than 6x in 2025 and is on track for 10x year-over-year growth by year-end.

As part of this next phase, Arya has appointed Melinda Phillips, former CEO of Thrive Skilled Pediatric Care (acquired by Aveanna), to lead its Care@Home Center of Excellence, where she will help scale AI adoption across the home care sector. A veteran operator of one of the nation’s largest post-acute providers, she brings deep industry experience to Arya’s technology-driven team, strengthening the company’s blend of insider expertise and outsider innovation.

“Arya represents exactly the kind of innovation post-acute care needs right now,” said Aike Ho, Partner at ACME Capital. “They’re pairing deep operational expertise with cutting-edge AI to unlock entirely new economics for providers, without sacrificing the humanity at the heart of care.”

To learn more, visit www.aryahealth.ai.

About Arya Health
Arya Health builds AI-powered digital agents that eliminate the administrative burden in post-acute care-so caregivers and coordinators can focus on patients, not processes. Purpose-built for home health, home care, and hospice, Arya integrates with leading EMRs to automate scheduling, compliance, onboarding, and more. By replacing manual office work with intelligent automation, Arya helps agencies cut costs, boost caregiver utilization, and scale efficiently-while keeping humanity at the heart of care.

Media contact:
BAM for Arya Health
[email protected] 

SOURCE Arya Health / BAM

Represents Ericsson’s latest AI investment as Voxel leads transformation from reactive to proactive workplace safety

SAN FRANCISCO, Oct. 29, 2025 — Voxel, the computer vision AI company revolutionizing workplace safety and risk, today announced a strategic investment from Ericsson Ventures, part of the Ericsson Group (NASDAQ: ERIC), a world leader in communications technology, offering hardware, software, and services to enable connectivity. This funding marks the latest significant investment Ericsson has made out of their Artificial Intelligence (AI) program.

Voxel recently completed a $44M Series B funding round, which was led by NewRoad Capital Partners with participation from Eclipse, Rite-Hite, Tokio Marine, MTech, HG Ventures and Whitestone. This round brings the company’s total funding of $64 million to date.

“This investment represents more than capital – it’s a strategic partnership built on shared vision,” said Vernon O’Donnell, CEO of Voxel. “Following our Series B, we’re focused on scaling our impact, and Ericsson brings both the global reach and technical expertise to help us transform workplace safety across industries worldwide.”

Jose Suarez, Head of Ericsson Ventures said, “Ericsson is committed to workplace safety as a core value. Voxel’s platform delivers tangible results, reducing workplace incidents and delivering immediate ROI to customers. We are excited to partner with Voxel to help companies protect their most important assets – their people.”

Voxel is hiring across all business units and offices. Open positions can be found here. To learn more about the solutions Voxel offers, please book time with our team.

About Voxel
Voxel is revolutionizing workplace safety with its AI-powered site visibility platform, designed to help organizations identify and mitigate risks in industrial environments. Using existing cameras, Voxel transforms basic video footage into actionable insights, enabling organizations to proactively make workplaces safer and more effective.

Voxel partners with businesses across industries such as warehousing, manufacturing, distribution, and insurance. By equipping businesses with the tools to identify risks before they happen, Voxel powers safer, more effective work environments.

SOURCE Voxel

The Partnership Pioneers New Pathways to Prepare for the Women’s Wealth Wave (™)

HOUSTON, Oct. 29, 2025 — In a first-of-its-kind collaboration set to reshape the financial landscape, Stavis Wealth and Curate Capital today announced a shared mission to unite the worlds of venture capital and wealth management, creating a powerful ecosystem where female founders, investors, and advisors can build, scale, and sustain wealth.

Both female-founded and female-led, the two firms share a bold vision: to close the gender wealth gap, rewrite outdated business models, and deliver integrated solutions that support women at every stage of their financial journeys, from launching their first company to preserving a multigenerational legacy.

The collaboration marks an expansion of the Women’s Wealth Wave (™), a Stavis Wealth initiative to educate, equip, and empower women but also to expand their access to meaningful financial opportunities. The initiative combines actionable learning, mentorship, and community with strategic partnerships, including ventures like Curate Capital, that connect women directly to capital, investment insights, and long-term planning resources. It builds on Stavis Wealth’s white-glove approach to holistic wealth management and legacy design, reflecting the firm’s long-standing commitment to advancing women’s financial confidence, access, and impact.

Curate Capital, founded by Carrie Colbert, has redefined venture capital by pioneering the concept of Influential Investing(™), leveraging the capital and talents of top-tier creators to power the growth of the brands in which they invest. The firm’s concept creates a win-win-win scenario for influencers, founders, and investors.

“The future of wealth creation isn’t about keeping investing and planning apart but about connecting them,” said Deborah Stavis, Founder and CEO of Stavis Wealth. “Because we’re an independent firm, with direct involvement alongside the Curate leadership team, our clients gain visibility and access to innovative opportunities. When investments are woven together with long-term planning to build real legacy, it creates a level of coordination and opportunity that most wealth management firms just aren’t built to deliver.”

Founded in 2020, Curate Capital has raised more than $30 million and invested in more than 20 women-led companies, including Frances Valentine, Live Tinted, Nori, and Curie, demonstrating that empowering women-led innovation isn’t just good business; it’s reshaping consumer categories. In fact, data shows that women control a staggering 85% of consumer spending. Curate believes that women are now building the solutions that they wish existed. 

“Originally as a venture capital outsider, I sought to bring a fresh perspective to the asset class, identifying two key gaps – women being underfunded despite overdelivering and a stagnant venture capital model ripe for innovation – and set out to address both,” said Carrie Colbert, Founding and General Partner of Curate Capital. “Women are redefining what wealth looks like and how it’s created. By aligning with Deborah and her team, we’re building a platform that helps women grow businesses, exit successfully, and translate those wins into enduring, multi-generational wealth.”

The partnership is also a direct response to one of the most persistent inequities in finance: women-led venture capital firms still receive less than 2% of total VC funding, and female advisors remain underrepresented in wealth management. Together, Stavis Wealth and Curate Capital aim to change that. Not only by investing in women and supporting female-led companies, but by cultivating the next generation of women investors, advisors, and industry leaders through mentorship.

This collaboration marks a pivotal step toward a future where financial empowerment isn’t an afterthought, it’s built into the foundation of entrepreneurship. Together, Stavis Wealth and Curate Capital are championing a new model for wealth creation: one that’s inclusive, intentional, and deeply transformative.

About Stavis Wealth
Stavis Wealth is a Houston-based wealth management firm providing comprehensive, holistic financial planning, investment management, estate planning, and customized life insurance solutions under one roof. Founder Deborah Stavis has served Houston families for over 35 years as a private wealth manager, having owned and operated two successful Registered Investment Advisory (RIA) firms, each amassing roughly 1 billion dollars in AUM. With this third round, Stavis Wealth is raising the bar once again, delivering a level of client experience and service excellence that other firms simply can’t match. Through initiatives like Women’s Wealth Wave(™), Stavis Wealth equips women with the education, strategies, and community to lead with confidence and protect their family legacy for generations.

About Curate Capital
Curate Capital is a Houston-based venture capital firm founded in 2020 by Carrie Colbert and dedicated to investing in female-founded consumer brands. Curate invests in extraordinary women building the products, services and technology the consumer wants for herself, her family and her life. Curate harnesses the power of influencers through its Influential Investing(™) program to directly impact portfolio company growth and drive outsized investor returns. Curate has invested in 20+ companies across categories like health & beauty, food & beverage, home & family, and fashion & apparel.

SOURCE Stavis Wealth

User Base Grows 483% in One Quarter as AI-Generated Code Outpaces Traditional Testing Capabilities

SEATTLE, Oct. 29, 2025 — TestSprite, the agentic testing tool for AI-native development, today announced the close of a $6.7 million seed round, bringing total funds raised to approximately $8.1 million. Trilogy Equity Partners led the round, with participation from both new and existing investors, including Techstars, Jinqiu Capital, MiraclePlus, Hat-trick Capital, Baidu Ventures, and EdgeCase Capital Partners. TestSprite is scaling to meet surging demand, growing 6X over the last three months, reaching over 35,000 users, following the launch of TestSprite 2.0 and its MCP server. The funding comes at a pivotal time, as the rise of AI-powered coding tools like Cursor, Windsurf, and GitHub Copilot accelerates development speed but creates a critical new bottleneck: testing and validating AI-generated code at scale. The oversubscribed round further cements TestSprite’s position as the testing backbone of the AI-native software development era.

Gartner projects that 90% of enterprise developers will use AI-assisted tools by 2028, up from under 14% in early 2024, indicating a massive total addressable market (TAM) exceeding $30–50 billion in the coming years. Andrew Ng, a globally recognized leader in AI and co-founder of Google Brain and founder of DeepLearning.AI, noted, “As AI gets better at generating code, ensuring that code works as intended becomes even more important. Reliable evaluation pipelines are critical for scaling trustworthy AI systems.”

“We’re witnessing a fundamental shift in software development. While everyone focuses on AI writing code faster, the real constraint is validation. TestSprite is the first to solve testing at the speed of AI, and the rapid growth quarter-over-quarter proves developers are desperate for this solution,” said Yuval Neeman, Managing Director, at Trilogy Equity Partners.

“Writing code is no longer the hard part—the real challenge is ensuring it behaves exactly as intended,” said Yunhao Jiao, CEO and co-founder of TestSprite. “AI coding tools like Cursor have made development 10x faster, but they’ve also created a new risk bottleneck: testing and validation can’t keep up. TestSprite is the autopilot layer that turns AI-written code into production-ready software without the manual testing overhead that’s slowing teams down.”

Many developers now find that vibe coding, building quickly with AI copilots, can become more frustrating and time-consuming than traditional development when debugging begins. TestSprite seeks to remove that pain entirely. Early adopters report cutting testing cycles from days to minutes, enabling teams to ship multiple releases per week instead of monthly.

TestSprite’s autonomous agent works directly inside AI IDEs and through MCP integration, enabling test-driven development throughout the coding process, not as a separate phase after code is written. TestSprite integrates natively into developers’ workflows, allowing developers to test without context switching to browsers or separate testing platforms. Developers validate and refine code iteratively as they build, producing production-ready software at completion without leaving their development environment.

TestSprite’s AI automatically generates frontend and backend tests, executes them, diagnoses failures, and proposes potential fixes through simple natural language commands. By enabling agentic testing where TestSprite’s AI agent writes, runs, and updates tests autonomously, it acts as an autopilot for software testing, dramatically accelerating developer velocity while maintaining quality.

TestSprite plans to channel funds toward expanding its engineering team to deepen capabilities in test generation, AI-powered test healing, and intelligent monitoring, while scaling infrastructure to support teams deploying thousands of code changes daily. TestSprite aims to become the industry standard testing layer for AI-native development by mid-2026.

About TestSprite
Based in Seattle, Washington, TestSprite is building the testing backbone for AI-native software development. Its MCP server integrates directly into developers’ AI IDEs, enabling continuous, test-driven development where code is validated iteratively throughout the entire build process—not just after it’s written. By supporting agentic coding workflows, where AI can autonomously write, test, and validate code, TestSprite functions as an autopilot for software quality, helping developers ship production-ready software at AI speed. Today, TestSprite powers the workflows of over 35,000 users from leading companies, such as Google, Apple, Adobe, Salesforce, ByteDance, Microsoft, and Meta, building the next generation of AI-native applications. Learn more at www.testsprite.com.

Press Contact:
Carmen Hughes
Ignite X
[email protected]
650.576.6444

SOURCE TestSprite

CustoMED’s cloud-based platform combines artificial intelligence and automation with 3D printing to generate surgical tools and implants directly from a surgeon’s pre-operative plan within minutes instead of weeks. The patient-specific devices are produced onsite or through certified partners and integrate seamlessly into existing surgical workflows, enabling fewer intraoperative errors and more predictable outcomes while allowing surgeons to maintain full creative and clinical control. The technology has already been used in hundreds of successful surgeries worldwide, with thousands more planned for the coming year.

“CustoMED’s patient-specific surgical tools enable more precise orthopedic surgeries through affordable, real-time solutions delivered directly into the operating room,” said Or Benifla, Co-founder of CustoMED. “By putting scalable, personalized technology directly in surgeons’ hands, our mission is to make computer-guided surgery fast, accessible, and routine, transforming what was once a boutique process into standard of care for every patient.”

CustoMED was founded by Dr. Amit Zabatani, Or Benifla, and Alon Jacobi, and originated from Sheba Medical Center’s 3D Printing & Innovation Lab, founded in 2018 by Dr. Dina Orkin together with the CustoMED co-founders. The lab has supported hundreds of surgeries across multiple hospital departments, making 3D technologies a routine part of patient care. CustoMED is part of Sheba Medical Center’s ARC Innovation ecosystem, which fosters clinician-led innovations and accelerates global deployment.

“CustoMED is embedding precision and surgeon-directed tools into everyday workflows, shortening the path from imaging to the operating room while preserving governance, quality, and safety,” said Prof. Eyal Zimlichman, Founder and Director of ARC Innovation and Chief Innovation, Transformation, and AI Officer at Sheba Medical Center. “The company exemplifies ARC’s mission to translate clinical insight into scalable, real-world impact.”

Funding proceeds will accelerate CustoMED’s expansion into additional automated orthopedic indications, support U.S. and EU regulatory milestones—with approvals anticipated for 2026—and enable the global deployment of its on-demand manufacturing model.

“We were immediately impressed by the ARC team’s world-class experience and CustoMED’s mission to improve surgical performance and patient outcomes,” added Raissa Hacohen, Managing Partner at Longevity Venture Partners. “CustoMED’s platform gives surgeons everywhere access to personalized planning and surgical tools that can raise the standard of care in orthopedic surgery.”

About CustoMED

CustoMED is a surgeon-first platform for AI-powered, patient-specific orthopedic surgery. Originating from Sheba Medical Center’s 3D Printing & Innovation Lab, CustoMED applies AI-driven automation and 3D printing to transform surgeons’ decisions into surgical guides and implants perfectly tailored to each patient. With hundreds of successful surgeries performed worldwide and $6M raised to date, CustoMED is scaling its solutions globally.

About ARC

ARC (Accelerate, Redesign, Collaborate), the innovation arm of Sheba Medical Center, founded and directed by Prof. Eyal Zimlichman, is shaping the future of medical innovation by connecting entrepreneurs and clinicians, advancing the development and implementation of new technologies, and creating breakthrough economic frameworks in healthcare. ARC’s unique model—the first of its kind in global healthcare—has evolved into a global blueprint, with a network of innovation centers in leading hospitals and research institutions across London, Melbourne, Singapore, Berlin, and New Zealand. ARC’s global network promotes technology-based medical solutions and accelerates the adoption of innovation within health systems worldwide.

ARC provides startups and researchers with exclusive access to Sheba’s core assets, clinical data and medical talent, while advancing the hospital’s vision to serve as a global hub for AI-driven medicine. The model’s success has already led to exits totaling approximately $1 billion, with profits reinvested to further accelerate Sheba’s AI and data revolution.

About Sheba Medical Center

The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and AI-based healthcare transformation. Sheba’s City of Health boasts acute-care, rehabilitation, children’s, cancer and geriatric hospitals, research and innovation hubs, medical simulation center, center for disaster response and a virtual hospital on one comprehensive campus in the center of Israel. Sheba serves as a true hospital without borders, welcoming patients and healthcare professionals from all over the world and consistently providing the highest-level medical care to all in need. For more information, visit: https://sheba-global.com

Photo – https://mma.prnewswire.com/media/2808183/MADE_by_SURGEONS.jpg

Contact:
Aviva Sapir 
Number 10 Strategies 
[email protected] 

SOURCE CustoMED

Fast growing National Security focused company adds additional resources to scale its Counter-UAS and Cybersecurity solutions

COLUMBIA, Md., Oct. 29, 2025 — BTS Software Solutions (BTS), a veteran-owned, fast-growing provider of intelligence operations, counter-UAS, cybersecurity, and data science solutions to national security focused agencies has announced a venture capital investment from Blue Delta Capital Partners, a growth-stage venture capital firm focused exclusively on the U.S. Federal Government market. The BTS management team will continue to be the majority owners of the company and will lead the veteran-owned firm to new heights. 

BTS is excited about this significant milestone in the Company’s evolution, with Blue Delta providing the equity capital, additional resources, and industry expertise needed to further enhance the Company’s proven capabilities for its national security customers, support future strategic acquisitions, and expand its impact to the Nation’s missions.

“We are delighted to secure this investment from Blue Delta as we embark on the next chapter in BTS’s growth,” said David Tohn, CEO of BTS. “Blue Delta’s deep and proven expertise in the national security market and their successful track record with companies like ours make them an ideal partner for our team as we continue to drive innovation for our national security and homeland defense customers and deliver unparalleled value to our Nation’s missions.”

“BTS has built an impressive reputation for delivering mission-critical solutions to our country’s national security customers and we are flattered to have the opportunity to back David and Dan and their team in supporting their growth plans, helping to amplify their impact in our core market,” said Kevin Robbins, co-founder of Blue Delta Capital Partners.

Dan Cummings, COO of BTS, added, “We are excited to have Blue Delta on our team, further accelerating our growth trajectory in counter-UAS and cybersecurity, while they also are fully aligning with BTS’s core values of Mission focus and dedication to our employees and customers.”

Assistance on the transaction for BTS came from Tidelock Partners, Next-Stage Partners, Miles & Stockbridge BDO, RSM and Aprio, while Blue Delta was assisted by Holland & Knight.

About  BTS
BTS Software Solutions (BTS) is a veteran-owned, fast-growing provider of intelligence operations, counter-UAS, cybersecurity, and data science solutions to national security focused agencies. Learn more at www.unleashbts.com.

About Blue Delta Capital Partners
Blue Delta, a growth-stage venture capital firm founded in 2009, focuses on the U.S. federal government services market. Learn more at www.bluedeltacapitalpartners.com

SOURCE BTS Software Solutions

SINGAPORE, Oct. 29, 2025 — ELD Asset Management Pte. Ltd. today announced its support for Daylight Energy’s recently disclosed $75 million financing package—combining $15 million in equity led by Framework Ventures with a $60 million project development facility led by Turtle Hill Capital—to scale a decentralized residential solar-and-storage network in the United States. The raise also includes participation from a16z crypto, Lerer Hippeau, M13, Room40 Ventures, EV3, Crucible Capital, Coinbase Ventures, and Not Boring Capital.

Under the initiative, Daylight will fund homeowner subscriptions that bundle rooftop solar and battery backup with no upfront cost, targeting initial rollouts in Illinois and Massachusetts. The company expects to pair monthly energy subscriptions with grid-service revenues by aggregating home batteries into a dispatchable virtual power resource. 

“This is operating leverage without unnecessary dilution,” said Jason Harrison, Senior Vice President at ELD Asset Management. “By aligning venture equity with a specialty project facility, the structure keeps execution focused on physical rollouts and measured electricity, not overhead—exactly the configuration long-horizon allocators want to see.” 

Why this matters

Daylight’s model targets a key friction in residential solar, where customer acquisition can exceed 60% of install cost across many programs. Its subscription aims to lower a typical household’s bill while creating a networked battery fleet that can earn market-based compensation during grid stress events—helping households and the grid simultaneously.

Technology & financing innovation

Daylight is launching DayFi, a protocol that maps metered electricity revenues from its distributed portfolio to on-chain claims, enabling transparent, energy-backed payouts. “Linking yield to measured electricity rather than speculative flows is the signal institutions have been waiting for,” Harrison added.

Framework Ventures Co-Founder Vance Spencer said Daylight can become the financing layer for distributed energy, while Turtle Hill Capital described the facility as purpose-built specialty credit that accelerates deployment. 

Market focus

The financing prioritizes installation in Illinois and Massachusetts, where interconnection rules and demand for resilience support faster cycle times and robust data collection—intended to shorten underwriting loops for lenders and offtakers. Daylight confirms subscriptions are live in both states, with DeFi-based financing to expand in Q4 2025. 

About Daylight Energy

Daylight turns homes into distributed power plants through a monthly energy subscription and an integrated battery network that trades with the grid. Backers include Framework Ventures and Andreessen Horowitz (a16z crypto). 

About ELD Asset Management

Founded in 2017 (UEN: 201725839Z), ELD Asset Management Pte. Ltd. is a Singapore-based firm advising clients on strategy and portfolio allocation informed by global macro and market research. More insights: eldglobal.com/news. Singapore Business Directory+2Companies.sg+2

Contact

Mr Luke Tan
ELD Asset Management
[email protected] 

Photo: https://mma.prnewswire.com/media/2808073/ELD_Asset_Management.jpg
Logo: https://mma.prnewswire.com/media/2808074/ELD_Asset_Management_Logo.jpg

SOURCE ELD Asset Management

CAMBRIDGE, Mass., Oct. 28, 2025 — Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series B financing. The proceeds will advance its lead preclinical oncology programs to Phase I clinical studies and accelerate development of Pinetree’s AbReptor™ platform. Participating investors include existing investors DSC Investment, WIDWIN Investment, STIC Ventures, Samho Green Investment, Atinum Investment, S&S Investment, SJ Investment Partners, Smilegate Investment, and Gauss Capital Management, as well as new investors Korea Investment Partners and SV Investment.

Founded in 2019, Pinetree is an industry leader in the targeted protein degradation (TPD) field, developing a novel class of modular bispecific and multispecific protein degraders designed to selectively eliminate disease-driving membrane-bound and extracellular proteins. The AbReptor™ platform has demonstrated compelling preclinical efficacy and safety in degrading receptor tyrosine kinases (RTKs) that drive tumor growth and resistance, including targets refractory to existing tyrosine kinase inhibitors (TKIs) and immune checkpoint therapies.

“The AbReptor™ platform has repeatedly demonstrated durable activity across a broad range of RTK targets, including models resistant to standard-of-care therapies, and has unlocked the potential to develop a novel class of degrading antibody drug conjugates (ADCs), which aim to overcome the limitations of traditional ADCs, including tolerability and limited durability. Our platform also offers new therapeutic approaches for targeting inflammatory cytokines in disease tissues, representing a potential alternative to current immunology and inflammation therapies,” said Ho-Juhn Song, Ph.D., Founder and CEO of Pinetree Therapeutics. “We are thrilled by the strong support from our investors and look forward to using these proceeds to advance differentiated therapies that address significant unmet clinical needs.”

The Series B financing will support IND-enabling studies and Phase I clinical trials for Pinetree’s lead programs, expand its multispecific degrader portfolio, and enable strategic collaborations to unlock new target classes. “We are excited to continue our partnership with Pinetree as they advance a highly differentiated platform with the potential to meaningfully impact patients with RTK-driven tumors,” said Yohan Kim, Executive Director of DSC Investment. “We see significant promise in Pinetree’s approach to overcoming resistance and improving tolerability, particularly for patients with limited treatment options.”

This financing follows a July 2024 collaboration with AstraZeneca, which included an exclusive global license option for Pinetree’s preclinical EGFR degrader candidate, valued at over $500 million in potential milestones and royalties, reflecting growing interest in AbReptor™ therapeutics. Pinetree continues to expand its pipeline and strategic partnerships to deliver novel TPD programs that aim to transform treatment for patients with hard-to-treat cancers and other diseases.

About Pinetree Therapeutics

Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor™ platform enables selective degradation of membrane-bound and extracellular proteins, offering a differentiated mechanism of action and durable therapeutic benefit. Pinetree is also advancing trispecific degraders and ADC-integrated platforms, and has entered strategic partnerships, including a licensing agreement with AstraZeneca. [https://www.pinetreetx.com/]

About DSC Investment

Founded in 2012, DSC Investment is one of the most active venture capital firms in South Korea, with approximately $1.0 billion in assets under management. The firm is committed to driving innovation and high growth across various industries, including bio-healthcare, deep tech, and content & commerce. It has built a strong track record of early-stage investments in some of South Korea’s most successful startups. With a continued focus on identifying high-potential entrepreneurs and transformative technologies, DSC Investment continues to expand its investment portfolio and support the next generation of global innovators. [http://dscinvestment.com/]

About Widwin Investment

Founded in 2008, Widwin Investment is a leading venture capital firm dedicated to identifying and nurturing high-growth opportunities across healthcare, software, and innovative technology platforms. The firm has established a strong track record in growth-stage and buyout investments, building a diverse portfolio across sectors where technology, scalability, and domain expertise drive success. While maintaining a selective investment approach, Widwin has made an outsized impact by supporting disruptive companies that are shaping the future of their industries. [http://widwininvest.com/]

Contact
Zachary Park
[email protected]
Pinetree Therapeutics, Inc
Cambridge, MA
+1-617-945-2309

SOURCE PineTree Therapeutics